Cargando…
Integrated metabolomics and lipidomics study of patients with atopic dermatitis in response to dupilumab
BACKGROUND: Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases. Dupilumab, a monoclonal antibody that targets the interleukin (IL)-4 and IL-13 receptors, has been widely used in AD because of its efficacy. However, metabolic changes occurring in patients with AD in r...
Autores principales: | Zhang, Lishan, Wen, Xueyi, Hou, Yibo, Yang, Yongshi, Song, Wei, Zeng, Yueping, Sun, Jinlyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632449/ https://www.ncbi.nlm.nih.gov/pubmed/36341398 http://dx.doi.org/10.3389/fimmu.2022.1002536 |
Ejemplares similares
-
The top 100 most cited articles in the last two decades of atopic dermatitis: A bibliometric analysis
por: Zhang, Lishan, et al.
Publicado: (2022) -
Dupilumab for atopic dermatitis
Publicado: (2019) -
Severe atopic dermatitis and dupilumab
por: Bernardo, Wanderley, et al.
Publicado: (2023) -
Is Dupilumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis?
por: Gelato, Federica, et al.
Publicado: (2023) -
Tape-Strip Proteomic Profiling of Atopic Dermatitis on Dupilumab Identifies Minimally Invasive Biomarkers
por: He, Helen, et al.
Publicado: (2020)